Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLC

Natasha B. Leighl, MD, BSc, MMSc, clinician investigator and member of the Cancer Clinical Research Unit (CCRU) at Princess Margaret Cancer Centre, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study (NCT05388669).

PALOMA-3 compared subcutaneous (SC) amivantamab-vmjw (Rybrevant) with intravenous (IV) administration of the agent, both in combination with lazertinib (Lazcluze) in patients with locally advanced or metastatic non­–small cell lung cancer (NSCLC) with documented EGFR exon 19 deletions or L858R substitution mutations. The combination was approved by the FDA in this patient population in August 2024.

Findings from PALOMA-3 presented during the 2024 IASLC World Conference on Lung Cancer showed that SC amivantamab met the noninferiority criteria for pharmacokinetic end points and objective response rate. In terms of efficacy the hazard ratios for progression-free survival and overall survival were 0.84 (95% CI, 0.64-1.10; P = .20) and 0.62 (95% CI, 0.42-0.92; P =.02), respectively. Additionally, patients who received SC amivantamab (n = 198) experienced a significantly decreased time in chair compared with those who received the IV formulation (n = 198) on day 1 of cycle 1, at 0.4 hours vs 6.5 hours, respectively, Leighl says. On day 1 of cycle 3, these figures were 0.6 hours vs 3.4 hours, in the SC (n = 163) and IV (n = 147) arms, respectively.

Health care resource utilization was also decreased with SC amivantamab vs the IV formulation, Leighl notes. On day 1 of cycle 1, SC administration led to a median active health care provider time of 5.6 hours compared with 7.6 hours for IV administration; these figures were 2.3 hours vs 4.4 hours on day 1 of cycle 3, respectively. Median patient time in the treatment room was also decreased with SC amivantamab vs IV administration, Leighl adds. On day 1 of cycle 1, patients in the SC group had a median time in the treatment room of 4.7 hours compared 7.0 hours in the IV group. These times were 1.5 hours vs 3.9 hours on day 1 of cycle 3, respectively.